**3. New perspectives for the treatment of histoplasmosis**

The decision to initiate treatment for histoplasmosis depends on the form and clinical presentation of the disease: Self-limited forms usually do not require treatment, in contrast to moderate and severe forms with persistent symptoms, extensive lesions, or chronic conditions. In these cases, administering an effective treatment

with minimal side effects, such as lipid amphotericin B followed by itraconazole for a sufficient period of time, is reasonable [10].

The use of nanocarriers for drug delivery has demonstrated their potential as an alternative and versatile technological platform for the treatment of intracellular infections caused by fungi of the species *H. capsulatum* [11]. However, future research is needed to improve the outcomes of this disease.

The chapters included in this book address all of these challenges related to the epidemiology, diagnosis, and treatment of histoplasmosis.
